Ascletis Pharma Inc.

Investors

Voluntary Announcement - FASN Inhibitor ASC40 Demonstrates Positive Phase II Topline Clinical Results from China Cohort of Patients with NASH
2021-03-09
Change of Principal Place of Business in Hong Kong
2021-03-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021
2021-03-03
Voluntary Announcement - Gannex Announces U.S. IND Approval and Initiation of Global Development of THR-beta Agonist ASC41 For NASH
2021-02-25
Voluntary Announcement - Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-Beta Agonist ASC41 Data Further Confirmed Doses for Phase II Trial in Patients with NASH
2021-02-21
Voluntary Announcement - Participation in Sagimet’S US$80 Million in Crossover Financing with Premium Investors
2021-02-11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021
2021-02-02
Change of Registered Office, Principal Share Registrar and Transfer Office in the Cayman Islands
2021-02-01
Next Day Disclosure Returns - Others
2021-01-14
Voluntary Announcement - Gannex Announces Positive Phase I Clinical Results on Its THR-beta Agonist ASC41
2021-01-12

3

© 2018 Ascletis Pharma Inc. All Rights Reserved
浙公网安备 33010802003344号浙ICP备 11050387号